Portable Liver Elastography for Regional Australia | Elastography Australia
Regional and rural Australian practices face a liver disease access gap. Guided elastography systems are changing that — here's what regional clinics need to know.
If you work in regional or rural Australia, you already know the gap. Liver elastography — the gold-standard non-invasive fibrosis test — is primarily available in major metropolitan centres. Your patients with indeterminate FIB-4 results face referral wait times of months, travel of hundreds of kilometres, and financial costs that many simply can't absorb.
The result is a predictable clinical outcome: delayed diagnosis, late-stage detection, and worse patient results from a disease that is highly manageable if caught early.
Guided elastography is changing this picture — and regional practices are increasingly at the front of that change.
The Regional Liver Disease Burden
Liver disease in regional Australia is not a minor footnote. Data from regional Victoria consistently shows MAFLD prevalence rates of 38–47% in community cohorts — substantially higher than many metropolitan estimates, driven by higher rates of obesity, T2DM, and metabolic syndrome in regional populations.
Hepatitis B burden is also significant in regional centres with large migrant communities. And chronic alcohol-related liver disease remains disproportionately prevalent in remote and regional Australia.
These populations face a compounding disadvantage: they are at higher clinical risk of significant liver fibrosis, and they have significantly less access to the diagnostic tests that would identify it.
What 'Portable' Actually Means for Elastography
The word portable has specific meaning in this context. Guided elastography systems — unlike large hospital-based MRI or CT — are compact, mains-powered units designed for clinical room deployment. The iLivTouch system, for example, is transportable, does not require specialised room preparation or radiation shielding, and can be set up in a standard consulting room.
This makes several deployment models practical for regional practices:
• Permanent installation in a regional GP practice or medical centre, where the device is operated by a trained clinical staff member.
• Visiting service model — a device is shared between two or more regional clinics on a scheduled rotation.
• Fly-in/drive-in specialist service — visiting hepatologists or gastroenterologists bring or have access to a local device on service days.
• Integration into Aboriginal Community Controlled Health Organisations (ACCHOs) — particularly relevant given the high metabolic disease burden in First Nations communities.
Training and Support for Regional Operators
One of the valid concerns from regional clinicians considering elastography is training. The learning curve for a device operated without real-time imaging guidance can be steep — particularly in regional settings where a low volume of scans means less repetitive practice.
Guided elastography substantially reduces this barrier. Real-time 2D ultrasound imaging shows the operator exactly where the probe is positioned relative to the liver parenchyma. The visual confirmation removes the main source of operator error in blind systems — incorrect probe positioning over an intercostal space, a rib, or a vessel.
Elastography Australia provides on-site training for all new installations, with remote ongoing support available. For regional practices, we offer extended training programmes and telehealth clinical consultation for clinical governance support.
The Economics for Regional Practices
The business case for regional elastography is often stronger than metropolitan practices assume — for a specific reason: there is no local competition.
A regional practice offering liver elastography has no nearby alternative. Patients who would otherwise travel 3–5 hours to a city for a referral-based scan will instead attend locally. GPs who previously had no option but to refer will build strong referral relationships with the elastography provider.
At 10 scans per week (a conservative assumption for a regional practice drawing from a broad catchment area), scan revenue at $150 per scan generates $6,000 per month. At approximately $45,000 device cost, the payback period is typically 7–10 months even at this conservative volume.
Integration with Telehealth and Remote Clinical Support
Elastography doesn't have to happen in isolation. Regional operators who produce a kPa result and B-mode image can share that data with specialist colleagues via telehealth in real time. The hepatologist or gastroenterologist reviewing the case from a metropolitan centre can confirm staging, advise on management, and reduce unnecessary travel for the patient.
This model — point-of-care elastography combined with telehealth clinical review — is already operating in several regional Australian contexts and represents a practical pathway for extending specialist reach without specialist travel.